NEW YORK (GenomeWeb) – Luxia Scientific announced this week an exclusive distribution agreement with Life Genomics for the commercialization of Luxia's microbiome test in Nordic countries.
Under the terms of the deal, Life Genomics will exclusively distribute Luxia's 1test1 test in Sweden, where the firm is based, as well as in Denmark, Finland, Iceland, and Norway. Additional terms were not disclosed.
The CE-IVD-marked 1test1 analyzes the bacterial content of the gut microbiome. Leveraging 16S rRNA sequencing, it provides information about bacterial diversity and the relative abundance of many bacterial groups that provide beneficial health benefits, Luxia said. According to the company's website, it is collaborating with the Integrated Biobank of Luxembourg to sequence the V3-V4 region of the 16S ribosomal RNA gene.
The 1test1 was launched in France last October and in Luxembourg in November.
Paris-based Luxia launched in June 2018 as a spinoff from the consulting firm of the same name. It was founded by Alessandra Cervino and develops diagnostic tests targeting the microbiome.
Gothenburg-based Life Genomics is a private genetic laboratory founded in 2014 as a spinoff of Tataa Biocenter to develop and offer genetic tests.